Evidence map›Paper›PMID 40590614›Full record

ArticleTherapeutic delivery2025

PEGylated MXene@AgNP nanocomposite for targeted release of docetaxel to breast carcinoma.

Pavni Mishra, Pooja Yadav, Manish K Chourasia, Vivek Dave

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pavni MishraDepartment of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, India.
Pooja YadavDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, India.
Manish K ChourasiaDivision of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, India.
Vivek DaveDepartment of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimMXene pertains to the family of two-dimensional materials with excellent surface area, biocompatibility, and many possibilities for surface functionalization. Owing to this, a multifunctional MXene nanocomposite was developed for targeted drug delivery at tumor site as current treatment regimens show increased adverse effects and limited selectivity.

methodMAX phase titanium aluminum carbide (Ti

resultThe final nanocomposite exhibits both thermal and pH-responsive in vitro drug delivery capabilities, with maximum drug release of 60% at pH 5.4 after 48 hours. The IC

conclusionThis work broadens the scope for therapeutic approach toward cancer through the development of nanocomposite by providing a potent and biocompatible alternative.

Indexed as

Antineoplastic AgentsBreast NeoplasmsMetal NanoparticlesNanocompositesPolyethylene GlycolsSilverTaxoidsCell Line, TumorCell SurvivalDocetaxelDrug CarriersDrug Delivery SystemsDrug LiberationFemaleHumansHydrogen-Ion ConcentrationAntineoplastic AgentsDocetaxelDrug CarriersMXeneNitritesPolyethylene GlycolsSilverTaxoidsTitaniumtitanium carbideTransition Elementsbreast cancerdocetaxelMxenenanocompositetargeted drug delivery

Identifiers

PMID40590614
PMCPMC12320828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.